<DOC>
	<DOC>NCT00074438</DOC>
	<brief_summary>This study will assess the efficacy and safety of different treatment regimens of rituximab (MabThera®/Rituxan®), corticosteroids, and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Eligibility criteria include, but are not limited to the following: Are between the ages of 18 and 80 years. Have been diagnosed with rheumatoid arthritis for at least 6 months. Have failed treatment (lack of efficacy) with at least 1 but no more than 5 diseasemodifying antirheumatic drugs or biologics (other than methotrexate).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>RA</keyword>
</DOC>